Adjusted. ORs for outcomes by maintenance P2Y12 treatment

Slides:

Advertisements

Similar presentations

Montalescot G et al. Lancet 2008;372:1-9. Mid- and long-term outcomes of STEMI patients treated with prasugrel, compared with clopidogrel and undergoing.

Advertisements

Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:

British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.

Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.

Is Bivalirudin Monotherapy Sufficient for Diabetic Patients with Acute Coronary Syndrome Undergoing PCI? Frederick Feit, Steven Manoukian, Ramin Ebrahimi,

Impact Of Diabetes Mellitus On The Safety And Effectiveness Of Bivalirudin In Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty:

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Fractional Flow Reserve Versus Angiography for Guiding.

Bivalirudin Monotherapy Improves 30-day Clinical Outcomes in Diabetics with Acute Coronary Syndrome: Report from the ACUITY Trial Frederick Feit, Steven.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Figure 1 A flow chart describing the systematic process followed for article selection. From: A systematic review of cost-effectiveness of percutaneous.

Supplementary Table 1 Independent Predictors of 2-Year Mortality

Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.

ADAPTABLE Inclusion/Exclusion

Ischaemic Heart Disease Acute Coronary Syndrome

ELIGIBILITY: MRC/BHF Heart Protection Study

Impact of gender on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty L Grinfeld,

Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Giuseppe Biondi Zoccai, MD

Becker RC, et al. Lancet 2009;373:919-28

Preventive Angioplasty in Myocardial Infarction Trial

Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

MACE rate among CAD severity groups (total 0

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Coronary revascularisation rate (total 5

Figure 4 Observational studies on multiple treatment strategies

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Tornado diagram of one-way deterministic sensitivity analysis.

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

Nat. Rev. Cardiol. doi: /nrcardio

Do the EXCEL and NOBLE Trial Results Change Meta-Analysis Findings?

Nat. Rev. Cardiol. doi: /nrcardio

Maintenance of Long-Term Clinical Benefit with

(A) Meta-analysis of repeat revascularisation in randomised trials.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Is Bivalirudin Monotherapy Sufficient for Diabetic Patients

For the HORIZONS AMI Investigators

Stent Versus Off-Pump Coronary Bypass Grafting in the Second-Generation Drug- Eluting Stent Era Gijong Yi, MD, PhD, Hyun-Chel Joo, MD, Young-Nam Youn,

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.

Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial

Characteristics of included studies

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

MATRIX: Radial vs. Femoral

Glenn N. Levine et al. JACC 2011;58:e44-e122

Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction.

Genetic predisposition to CHD modifies the increased CHD risk associated with smoking (*) ORs adjusted for age, gender, total energy intake, alcohol intake,

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction (STEMI) studies; (A) glycoprotein.

Ticagrelor versus prasugrel; risk ratio with 95% CIs for the primary composite end point, primary composite end point in those undergoing PCI, myocardial.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Improved Long-Term Survival for Diabetic Patients With Surgical Versus Interventional Revascularization Paul Kurlansky, MD, Morley Herbert, PhD, Syma.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;

Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference. Multivariable-adjusted HRs and 95% CIs for outcomes for waist circumference.

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Presentation transcript:

Adjusted. ORs for outcomes by maintenance P2Y12 treatment Adjusted* ORs for outcomes by maintenance P2Y12 treatment. *Adjusted for age>65 years, anaemia, bivalirudin versus heparin±glycoprotein IIb/IIIa inhibitor, new P2Y12 maintenance dose, creatinine clearance ≤60 vs >60 mL/min, current smoker, diabetes, drug-el... Adjusted* ORs for outcomes by maintenance P2Y12 treatment. *Adjusted for age>65 years, anaemia, bivalirudin versus heparin±glycoprotein IIb/IIIa inhibitor, new P2Y12 maintenance dose, creatinine clearance ≤60 vs >60 mL/min, current smoker, diabetes, drug-eluting stent, female sex, femoral versus radial access, hyperlipidaemia, hypertension, Killip class≥II, preprocedural TIMI flow 0/1 vs 2/3, history of coronary artery bypass graft, previous percutaneous coronary intervention, previous MI, single-vessel disease. MACE, major adverse cardiac events (death or myocardial infarction, ischaemia-driven revascularisation or stroke); MI, myocardial infarction; NACE, net adverse clinical events (death or myocardial infarction, ischaemia-driven revascularisation, stroke or bleeding); TIMI, Thrombolysis In Myocardial Infarction. Kurt Huber et al. Open Heart 2017;4:e000677 ©2017 by British Cardiovascular Society